235 related articles for article (PubMed ID: 31903790)
1. Clinical significance of chemokine receptor antagonists.
Miao M; De Clercq E; Li G
Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):11-30. PubMed ID: 31903790
[No Abstract] [Full Text] [Related]
2. Targeting chemokine receptors for HIV: past, present and future.
Fricker SP
Future Med Chem; 2015; 7(17):2311-5. PubMed ID: 26627446
[No Abstract] [Full Text] [Related]
3. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
4. Chemokine receptors as therapeutic targets.
Yoshie O
Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):189-96. PubMed ID: 23994796
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
Seibert C; Sakmar TP
Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
[TBL] [Abstract][Full Text] [Related]
6. Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.
Visseaux B; Charpentier C; Collin G; Bertine M; Peytavin G; Damond F; Matheron S; Lefebvre E; Brun-Vézinet F; Descamps D;
PLoS One; 2015; 10(8):e0134904. PubMed ID: 26247470
[TBL] [Abstract][Full Text] [Related]
7. Redox regulation of chemokine receptor expression.
Saccani A; Saccani S; Orlando S; Sironi M; Bernasconi S; Ghezzi P; Mantovani A; Sica A
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2761-6. PubMed ID: 10716998
[TBL] [Abstract][Full Text] [Related]
8. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.
Singh IP; Chauthe SK
Expert Opin Ther Pat; 2011 Feb; 21(2):227-69. PubMed ID: 21219250
[TBL] [Abstract][Full Text] [Related]
9. Chemokine receptor antagonists: part 2.
Pease JE; Horuk R
Expert Opin Ther Pat; 2009 Feb; 19(2):199-221. PubMed ID: 19441918
[TBL] [Abstract][Full Text] [Related]
10. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3.
Gao P; Zhou XY; Yashiro-Ohtani Y; Yang YF; Sugimoto N; Ono S; Nakanishi T; Obika S; Imanishi T; Egawa T; Nagasawa T; Fujiwara H; Hamaoka T
J Leukoc Biol; 2003 Feb; 73(2):273-80. PubMed ID: 12554804
[TBL] [Abstract][Full Text] [Related]
11. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.
D'Antoni ML; Mitchell BI; McCurdy S; Byron MM; Ogata-Arakaki D; Chow D; Mehta NN; Boisvert WA; Lefebvre E; Shikuma CM; Ndhlovu LC; Baumer Y
J Leukoc Biol; 2018 Dec; 104(6):1241-1252. PubMed ID: 30088682
[TBL] [Abstract][Full Text] [Related]
12. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
Andrews G; Jones C; Wreggett KA
Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
[TBL] [Abstract][Full Text] [Related]
13. What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy?
Jülg B; Goebel FD
Infection; 2005 Oct; 33(5-6):408-10. PubMed ID: 16258879
[TBL] [Abstract][Full Text] [Related]
14. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).
Agrawal L; Vanhorn-Ali Z; Alkhatib G
J Leukoc Biol; 2002 Nov; 72(5):1063-74. PubMed ID: 12429730
[TBL] [Abstract][Full Text] [Related]
15. Expression and function of chemokine receptors on human thymocytes: implications for infection by human immunodeficiency virus type 1.
Taylor JR; Kimbrell KC; Scoggins R; Delaney M; Wu L; Camerini D
J Virol; 2001 Sep; 75(18):8752-60. PubMed ID: 11507220
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological blockers of CCR5 and CXCR4 improve recovery after traumatic brain injury.
Friedman-Levi Y; Liraz-Zaltsman S; Shemesh C; Rosenblatt K; Kesner EL; Gincberg G; Carmichael ST; Silva AJ; Shohami E
Exp Neurol; 2021 Apr; 338():113604. PubMed ID: 33453212
[TBL] [Abstract][Full Text] [Related]
17. Expression of chemokines and chemokine receptors during human renal transplant rejection.
Segerer S; Cui Y; Eitner F; Goodpaster T; Hudkins KL; Mack M; Cartron JP; Colin Y; Schlondorff D; Alpers CE
Am J Kidney Dis; 2001 Mar; 37(3):518-31. PubMed ID: 11228176
[TBL] [Abstract][Full Text] [Related]
18. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer.
Weitzenfeld P; Ben-Baruch A
Cancer Lett; 2014 Sep; 352(1):36-53. PubMed ID: 24141062
[TBL] [Abstract][Full Text] [Related]
19. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges.
Lefere S; Devisscher L; Tacke F
Expert Opin Investig Drugs; 2020 Feb; 29(2):89-92. PubMed ID: 31952447
[No Abstract] [Full Text] [Related]
20. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
